Navigation Links
Ovalum Ltd. Announces Success in Coronary Cases Using CiTop™ ExPander™ Guidewire
Date:7/11/2008

Following First-in-Man study success, Ovalum Ltd. launches a multicenter study using the CiTop™ technology in the coronary arteries. Ovalum Ltd., a privately held Israeli medical device company, has announced today successful experiences using CiTop™ ExPander™ Guidewire in traversing chronic total occlusions in the coronary arteries.

Rehovot , Israel (PRWEB) July 11, 2008 -- Following First-in-Man study success, Ovalum Ltd. launches a multicenter study using the CiTop™ technology in the coronary arteries.

Ovalum Ltd., a privately held Israeli medical device company, has announced today successful experiences using CiTop™ ExPander™ Guidewire in traversing chronic total occlusions in the coronary arteries.

Chronic Total Occlusion (CTO) is one of the main challenges that Interventional Cardiologists face today. Attempts in opening coronary CTOs by using mechanical wires are ranging from 26% to 85% and are operator dependent. In order to increase success rate and make it less operator-dependent, the CiTop™ ExPander™ Guidewire was designed. The CiTop™ ExPander™ Guidewire is a 0.014" Guidewire which combines conventional guidewire navigational properties with a tip dilation feature to aid in releasing a wedged guidewire and allow its advancement through difficult occlusions.

The company has completed successfully its First-in-Man study in the use of the CiTop™ ExPander™ Guidewire in the coronary arteries. Dr. Keyur H. Parikh, The Heart Care Clinic/Care Cardiovascular Consultants (Ahmedabad, India), Principle Investigator of the study has said: "Ovalum with its CiTop™ wire has discovered an approach to a safe and sure way to cross CTOs. Chronic Total Occlusions is one of the last frontiers of the Cardiologists, the CiTop™ wire has shown me an approach towards that last frontier.... "

Ovalum is launching this July its Multicenter study to evaluate the performance of the CiTop™ ExPander™ Guidewire in crossing CTOs in the coronary arteries. Dr. Farrel Hellig from the Sunninghill Hospital in Johannesburg, South Africa, has concluded that "…the CiTop™ was successful with an excellent result" after an initial experience with the CiTop™ ExPander™ Guidewire.

The company has submitted the CiTop™ ExPander™ Guidewire to its notified body in the European Economic Area and is expecting to receive its CE marking during the fourth quarter of 2008. In addition, the company has completed the CiTop™ ExPander™ Guidewire 510K application to the FDA which will be submitted next month.

The CiTop™ ExPander™ Guidewire provides a simpler and more efficient means to open the Chronic Total Occlusion, thus avoiding the need for coronary bypass surgery. Noam Shamay, founder and CEO of Ovalum Ltd. said: "I am enthusiastic about the opportunity to introduce a significantly less invasive therapeutic option for coronary CTO patients".

About Ovalum

Ovalum Ltd. was founded in March 2005 by Noam Shamay and Eitan Finkelstein. Located in Rabin Science Park Rehovot, Israel, OVALUM Ltd. Develops, manufactures and markets breakthrough products for the minimally invasive cardiology and interventional radiology markets designed specifically for the most challenging arterial procedures.

Ovalum Ltd. investors: Ziegler Meditech equity Partners LP and Smithfield Fiduciary LLC, represented by Eitan Machover (Director) and Pontifax LP represented by Tomer Kariv (Director).

CiTop™, CoBra™, TraVerse™ are all trademarks of Ovalum Ltd.

###


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe
2. Ovalum Ltd. Received Clearance to Market the CiTop™ Product-Line in Israel
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , December 5, 2016 ... "Cell Expansion Market, by Products (Consumable, Instruments, Automated ... (Regenerative Medicine and Stem Cell Research, Cancer, and ... Institutes, Cell Banks) - Global Revenue, Trends, Growth, ... Scalar Market Research, the global cell expansion market ...
(Date:12/5/2016)... , Dec 5, 2016 Research and ... "DNA Sequencing - Technologies, Markets and Companies" to ... , ... briefly reviews basics of human genome variations, development of sequencing ... described as well as companies developing them. Various applications of ...
(Date:12/4/2016)... and CAMBRIDGE, Mass. ... , Dec. 4, 2016 SystemOne, ... connected diagnostics software platforms for the developing world, ... "Anywhere. Care.™" a reality with its portable and ... entered into a development and license agreement to ...
(Date:12/2/2016)... Dec. 2, 2016 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced the appointment of ... industry consultant, and private healthcare investor, to its Board ... leader with clinical and strategic experience at the highest ... and CEO. "As one of the world,s leading orthopedic ...
Breaking Biology Technology:
(Date:11/17/2016)... 2016 Global Market Watch: Primarily supported ... Population-Based Banks and Academics) market is to witness a value ... shows the highest Compounded Annual Growth Rate (CAGR) of 10.75% ... the analysis period 2014-2020. North America ... by Europe at 9.56% respectively. ...
(Date:11/15/2016)... Nov. 15, 2016  Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...
(Date:11/14/2016)... , Nov. 14, 2016  Based ... identification market, Frost & Sullivan recognizes FST ... Sullivan Award for Visionary Innovation Leadership. FST ... the biometric identification market by pioneering In ... solution for instant, seamless, and non-invasive verification. ...
Breaking Biology News(10 mins):